Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$27,000.00

Hormonal contraceptive use and breast cancer risk in women with a germline pathogenic variant in the BRCA1 or BRCA2 gene

FY 2024-25

Summary
Hormonal contraceptive use results in an increased risk of developing breast cancer in the general population, but its association in women with an inherited mutation in the BRCA1 or BRCA2 gene is not known. In the largest study to date, our team reported a 29% increase in the risk of developing BRCA1-breast cancer with use of oral hormonal contraceptives (‘the pill’) but had no impact on BRCA2-breast cancer. However, we did not evaluate the impact of other methods (e.g. implants, IUD, patch) or formulation (e.g. estrogen + progestin, progestin-only) in this unique population. This leaves a critical gap in our understanding in women with BRCA mutations, who already face a higher lifetime risk of breast cancer, often at a young age. Thus, the aim of this study is to evaluate whether the relationship between hormonal contraceptives and breast cancer risk in women with a BRCA mutation varies by method or formulation. A prospective cohort study will be conducted using an international cohort of 19,000 women with a BRCA mutation. Participants complete questionnaires about personal medical history, reproductive history and contraceptive use (including duration of use, medication name and method of administration), and are followed every two years. Multivariate regression models will be conducted to identify associations between contraceptive use and breast cancer risk, overall and by BRCA mutation type. The results of this study will contribute to the development of evidence-based guidelines for the use of contraceptives among women with a BRCA mutation and aid with clinical decision making, ultimately reducing the risk of breast cancer.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
530905
Name
Rajkumar Anita
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Hormonal contraceptive use and breast cancer risk in women with a germline pathogenic variant in the BRCA1 or BRCA2 gene
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Breast Cancer; Contraceptives; Epidemiology; Genetics; Hormones; Risk Factors
Abstract
Hormonal contraceptive use results in an increased risk of developing breast cancer in the general population, but its association in women with an inherited mutation in the BRCA1 or BRCA2 gene is not known. In the largest study to date, our team reported a 29% increase in the risk of developing BRCA1-breast cancer with use of oral hormonal contraceptives (‘the pill’) but had no impact on BRCA2-breast cancer. However, we did not evaluate the impact of other methods (e.g. implants, IUD, patch) or formulation (e.g. estrogen + progestin, progestin-only) in this unique population. This leaves a critical gap in our understanding in women with BRCA mutations, who already face a higher lifetime risk of breast cancer, often at a young age. Thus, the aim of this study is to evaluate whether the relationship between hormonal contraceptives and breast cancer risk in women with a BRCA mutation varies by method or formulation. A prospective cohort study will be conducted using an international cohort of 19,000 women with a BRCA mutation. Participants complete questionnaires about personal medical history, reproductive history and contraceptive use (including duration of use, medication name and method of administration), and are followed every two years. Multivariate regression models will be conducted to identify associations between contraceptive use and breast cancer risk, overall and by BRCA mutation type. The results of this study will contribute to the development of evidence-based guidelines for the use of contraceptives among women with a BRCA mutation and aid with clinical decision making, ultimately reducing the risk of breast cancer.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Rajkumar, Anita
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~